This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective
Leukemia Open Access 17 March 2023
-
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Leukemia Open Access 29 June 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I et al. (eds) Therapy-related myeloid neoplasms. International Agency for Research on Cancer (IARC): Lyon, France, 2008; pp 127–129.
Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137–2145.
Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127: 197–205.
Bacher U, Haferlach C, Alpermann T, Schnittger S, Kern W, Haferlach T . Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma 2013; 54: 639–642.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820–829.
Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002; 16: 2366–2378.
Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T . Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120–125.
Bacher U, Haferlach C, Alpermann T, Kern W, Schnittger S, Haferlach T . Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Haematologica 2011; 96: 1284–1292.
Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood 2010; 115: 1985–1992.
Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA et al. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol 2008; 21: 1394–1402.
Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell 2011; 20: 591–605.
Voso MT, Fabiani E, Fianchi L, Falconi G, Criscuolo M, Santangelo R et al. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2013; 27: 982–985.
Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2340–2347.
Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079–1089.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
Wang, Hasserjian and Garcia-Manero designed the study. OK, Hasserjian, Young and Patel collected the data. OK, Fox, Stingo, Zuo and Wang analyzed the data. OK, Wang, Hasserjian, Medeiros, Fox and Stingo wrote the paper.
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Ok, C., Hasserjian, R., Fox, P. et al. Application of the International Prognostic Scoring System-Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 28, 185–189 (2014). https://doi.org/10.1038/leu.2013.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.191
This article is cited by
-
Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective
Leukemia (2023)
-
The International Consensus Classification of myelodysplastic syndromes and related entities
Virchows Archiv (2023)
-
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Leukemia (2021)
-
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
Leukemia (2019)
-
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes
Annals of Hematology (2018)